Our 3-year prospective case-control study assessing 17 angiogenesis-related proteins demonstrated that the most reliable major adverse limb event (MALE) predictor in PAD patients was hepatocyte growth factor (HGF). This evidence concerns the gene HGF and peripheral arterial disease.